Lumida
/NAMS
⌘K
NewAmsterdam Pharma Company NV

NewAmsterdam Pharma Company NV

NAMS
$22.80USD+4.30%+0.94 today

MARKET CAP

2.7B

P/E (TTM)

FWD P/E

DAY RANGE

$21 – $23

52W RANGE

$21
$42
STATEMENT·Income statement
USD · GAAP
METRICFY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$102.7M$14.1M$45.6M$22.5M
YoY %-86.3%+223.4%-50.6%
P / Sales2.1x69.7x53.2x184.6x
EV / Sales-2.0x49.7x38.6x166.7x
Gross Profit, Adj.$102.7M$14.1M$45.6M$22.5M
YoY %-86.3%+223.4%-50.6%
Margin %100.0%100.0%100.0%100.0%
EV / Gross Profit-2.0x49.7x38.6x166.7x
EBITDA, Adj.$-3.5M$-182.9M$-176.2M$-225.5M
YoY %-5055.5%+3.7%-28.0%
Margin %-3.5%-1298.2%-386.7%-1001.9%
EV / EBITDA58.5x-3.8x-10.0x-16.6x
EBIT$-3.6M$-183.0M$-176.3M$-225.7M
YoY %-5043.9%+3.6%-28.0%
Margin %-3.5%-1298.6%-386.9%-1002.9%
EV / EBIT58.3x-3.8x-10.0x-16.6x
Net Income$-22.6M$-176.9M$-241.6M$-203.8M
YoY %-681.7%-36.5%+15.6%
Net Margin-22.0%-1255.8%-530.3%-905.7%
EPS (GAAP)-$1.19-$2.15-$2.66-$1.72
YoY %-80.7%-23.7%+35.3%